Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Status:
Completed
Trial end date:
2019-12-24
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies the side effects of and compares apixaban and
dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism.
Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks
off and moves through the bloodstream. Patients with cancer are at increased risk for venous
thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming
or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin
is more effective in reducing blood clots in patients with cancer related venous
thromboembolism.
ADAM-VTE